The Cigna Group CI
Verdict: Strong sell. Fair value $331 against a price of $284 on 6 Jan 2026, 17% above the price.
In plain words
The case for: Narrow competitive moat provides durability. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income has declined for two consecutive years, falling 23% in 2023 and a further 33% in 2024..... The OCF to Net Income ratio has expanded dramatically from a healthy 1.29 in 2022 to an unusually....
Main risks
- Collapsing Profitability: Net margin has deteriorated sharply from 3.7% in 2022 to a very low 1.4% in 2024, despite strong revenue growth, indicating severe margin pressure or poor cost control.
- Poor Returns on Capital: ROE (8.4%), ROIC (6.5%), and ROIIC (8.2%) are all at low levels, suggesting inefficient use of capital and that recent investments are not generating adequate returns for shareholders.
- Elevated Leverage: A Net Debt to EBITDA ratio of approximately 3.7x is high, indicating increased financial risk. This is particularly concerning given the simultaneous decline in profitability.
- Net Income has declined for two consecutive years, falling 23% in 2023 and a further 33% in 2024....
- The OCF to Net Income ratio has expanded dramatically from a healthy 1.29 in 2022 to an unusually...
- Intense competitive environment